K Hayashi1, S Masuda, H Kimura. 1. Pharmaco-Business Innovation Laboratory, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan. pbi_info@mol.f.u-tokyo.ac.jp
Abstract
WHAT IS KNOWN AND OBJECTIVE: The increasing cost of drug research and development and the decreasing number of new drugs being launched are serious issues for pharmaceutical companies. Biomarkers for predicting drug effectiveness are regarded as useful tools for combating these trends. However, the extent to which these biomarkers actually help in improving drug development is unclear. Here, we investigated the efficiency of biomarker usage in oncology drug development by focusing on stratification markers. METHODS: Anti-tumour agents for which clinical studies were initiated between 1998 and 2009 were identified using commercially available data sources, and clinical trials registered in ClinicalTrials.gov were examined to identify the use of stratification marker. Phase transition probability for each clinical phase was calculated and analysed along with various other factors that may affect the efficiency of the development process. RESULTS AND DISCUSSION: Of 908 anti-tumour agents identified, 121 (13·3%) utilized stratification markers in their clinical studies. Phase I, II and III transition probabilities for all agents were 76·4%, 50·8% and 58·5%, respectively. Corresponding Phase I, II and III transition probabilities of agents developed with stratification markers of 90·4%, 69·0% and 85·0%, respectively, were significantly higher than those for agents without stratification markers. Orphan designation positively affected phase transition probabilities of agents without stratification markers in all phases, while it did not affect transition probabilities of agents with stratification markers, except for Phase II. This shows that stratification markers help improve the probability of success in the development of agents without orphan designation. WHAT IS NEW AND CONCLUSION: Stratification markers contribute to improving the efficiency of development of anti-cancer drugs. The majority of non-orphan drugs are still being developed without stratification markers. Finding reliable stratification markers for all drugs should improve the success rates in drug development.
WHAT IS KNOWN AND OBJECTIVE: The increasing cost of drug research and development and the decreasing number of new drugs being launched are serious issues for pharmaceutical companies. Biomarkers for predicting drug effectiveness are regarded as useful tools for combating these trends. However, the extent to which these biomarkers actually help in improving drug development is unclear. Here, we investigated the efficiency of biomarker usage in oncology drug development by focusing on stratification markers. METHODS: Anti-tumour agents for which clinical studies were initiated between 1998 and 2009 were identified using commercially available data sources, and clinical trials registered in ClinicalTrials.gov were examined to identify the use of stratification marker. Phase transition probability for each clinical phase was calculated and analysed along with various other factors that may affect the efficiency of the development process. RESULTS AND DISCUSSION: Of 908 anti-tumour agents identified, 121 (13·3%) utilized stratification markers in their clinical studies. Phase I, II and III transition probabilities for all agents were 76·4%, 50·8% and 58·5%, respectively. Corresponding Phase I, II and III transition probabilities of agents developed with stratification markers of 90·4%, 69·0% and 85·0%, respectively, were significantly higher than those for agents without stratification markers. Orphan designation positively affected phase transition probabilities of agents without stratification markers in all phases, while it did not affect transition probabilities of agents with stratification markers, except for Phase II. This shows that stratification markers help improve the probability of success in the development of agents without orphan designation. WHAT IS NEW AND CONCLUSION: Stratification markers contribute to improving the efficiency of development of anti-cancer drugs. The majority of non-orphan drugs are still being developed without stratification markers. Finding reliable stratification markers for all drugs should improve the success rates in drug development.
Authors: Kristian Taipale; Ilkka Liikanen; Juuso Juhila; Riku Turkki; Siri Tähtinen; Matti Kankainen; Lotta Vassilev; Ari Ristimäki; Anniina Koski; Anna Kanerva; Iulia Diaconu; Vincenzo Cerullo; Markus Vähä-Koskela; Minna Oksanen; Nina Linder; Timo Joensuu; Johan Lundin; Akseli Hemminki Journal: Mol Ther Date: 2015-08-27 Impact factor: 11.454
Authors: Joseph J Locascio; Shirley Eberly; Zhixiang Liao; Ganqiang Liu; Ashley N Hoesing; Karen Duong; Ana Trisini-Lipsanopoulos; Kaltra Dhima; Albert Y Hung; Alice W Flaherty; Michael A Schwarzschild; Michael T Hayes; Anne-Marie Wills; U Shivraj Sohur; Nicte I Mejia; Dennis J Selkoe; David Oakes; Ira Shoulson; Xianjun Dong; Ken Marek; Bin Zheng; Adrian Ivinson; Bradley T Hyman; John H Growdon; Lewis R Sudarsky; Michael G Schlossmacher; Bernard Ravina; Clemens R Scherzer Journal: Brain Date: 2015-07-28 Impact factor: 13.501
Authors: I Ubink; H J Bloemendal; S G Elias; M A Brink; M P Schwartz; Y C W Holierhoek; P M Verheijen; A W Boerman; R H J Mathijssen; W W J de Leng; R A de Weger; W M U van Grevenstein; M Koopman; M P Lolkema; O Kranenburg; I H M Borel Rinkes Journal: BMC Cancer Date: 2017-04-19 Impact factor: 4.430
Authors: Jayson L Parker; Sebnem S Kuzulugil; Kirill Pereverzev; Stephen Mac; Gilberto Lopes; Zain Shah; Ashini Weerasinghe; Daniel Rubinger; Adam Falconi; Ayse Bener; Bora Caglayan; Rohan Tangri; Nicholas Mitsakakis Journal: Cancer Med Date: 2021-02-23 Impact factor: 4.452